J Am Pharm Assoc (2003). 2021 Nov-Dec;61(6):813-818.e1. doi: 10.1016/j.japh.2021.06.023. Epub 2021 Jul 3.
The Cannabis Act, introduced in Canada in 2018, legalized the use of recreational cannabis. The impact of the announcement and implementation of this act on patient self-reporting of cannabis use has not been explored.
The study objective was to determine if patient self-reported cannabis use increased after the announcement and implementation of legislative changes to legalize recreational cannabis.
A repeated cross-sectional design was used for a retrospective chart review of patients seen at a pharmacist-led primary care clinic. A convenience sample of patient records was divided into 3 panels, corresponding with the preannouncement (November 1, 2013-October 4, 2015), postannouncement (October 5, 2015-October 16, 2018), and postimplementation (October 17, 2018-October 17, 2019) stages of the legalization of recreational cannabis. Search terms used included cannabis, marijuana, marihuana, recreational drugs, natur∗, medicinal, pot, joint, oil, butter, brownies, edibles, cannabin∗, THC, tetrahydro∗, sativa, and indica (∗ = string wild card). The frequency of reporting use and the number of queries related to cannabis were assessed. The analysis of variance test and Pearson correlation (chi-square) were used to compare the 3 panels.
A total of 298 patient charts were included in the analysis. One hundred, 99, and 99 patient charts corresponded with panels 1, 2, and 3, respectively. At each time point, 6%, 8%, and 14% of the patients reported cannabis use (P = 0.03). A statistically significant increase in topical oil use and a decrease in prescription tablet or capsule use between panels 1 and 3 (P = 0.036) were identified.
This study found an increase in self-reporting of cannabis use across the 3 consecutive panels. The change in the product formulations used may reflect the various products available. Frontline pharmacists are encouraged to initiate conversations regarding cannabis use as part of routine practice.
2018 年加拿大引入的《大麻法》使娱乐用大麻合法化。该法案的公布和实施对患者自行报告大麻使用情况的影响尚未得到探索。
本研究旨在确定在娱乐用大麻合法化的立法变更公布和实施后,患者自我报告的大麻使用量是否增加。
使用回顾性图表审查,对药剂师主导的初级保健诊所就诊的患者进行重复横断面设计。将患者记录的便利样本分为 3 个面板,分别对应于大麻合法化的公告前(2013 年 11 月 1 日-2015 年 10 月 4 日)、公告后(2015 年 10 月 5 日-2018 年 10 月 16 日)和实施后(2018 年 10 月 17 日-2019 年 10 月 17 日)阶段。使用的搜索词包括大麻、大麻、大麻、娱乐性药物、天然、药用、锅、关节、油、黄油、布朗尼、可食用、大麻素、四氢大麻酚、四氢大麻酚、西塔、因达(∗=字符串通配符)。评估报告使用频率和与大麻相关的查询数量。方差检验和 Pearson 相关性(卡方)用于比较 3 个面板。
共纳入 298 份患者图表进行分析。第 1、2 和 3 个面板分别对应 100、99 和 99 份患者图表。在每个时间点,分别有 6%、8%和 14%的患者报告使用大麻(P=0.03)。发现从第 1 个面板到第 3 个面板,局部油的使用呈统计学显著增加,而处方片剂或胶囊的使用呈下降趋势(P=0.036)。
本研究发现 3 个连续面板中自我报告的大麻使用量增加。使用的产品配方的变化可能反映了各种可用产品。鼓励一线药剂师将关于大麻使用的讨论作为常规实践的一部分。